Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Neuroblastoma
ADR ID BADD_A07474
ADR Hierarchy
05      Endocrine disorders
05.01      Adrenal gland disorders
05.01.04      Adrenal neoplasms
05.01.04.001      Neuroblastoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.30      Nervous system neoplasms malignant and unspecified NEC
16.30.03      Nervous system neoplasms malignant NEC
16.30.03.002      Neuroblastoma
17      Nervous system disorders
17.20      Nervous system neoplasms malignant and unspecified NEC
17.20.03      Nervous system neoplasms malignant NEC
17.20.03.002      Neuroblastoma
Description A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) [MeSH]
MedDRA Code 10029260
MeSH ID D009447
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Neuroblastoma | Neuroblastoma NOS | Neuroblastomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00535Crizotinib0.000302%
BADD_D01136Imatinib0.000224%
BADD_D01213Isotretinoin0.000257%
BADD_D01679Paroxetine0.000043%
BADD_D02105Tacrolimus0.000297%
The 1th Page    1    Total 1 Pages